SECUKINUMAB and MALAISE

Overview

MALAISE is the #8 most commonly reported adverse reaction for SECUKINUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 9,100 FDA adverse event reports linking SECUKINUMAB to MALAISE. This represents approximately 1.9% of all 482,303 adverse event reports for this drug.

SECUKINUMAB has an overall safety score of 65 out of 100. Patients taking SECUKINUMAB who experience malaise should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

MALAISE is a less commonly reported adverse event for SECUKINUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of SECUKINUMAB

In addition to malaise, the following adverse reactions have been reported for SECUKINUMAB:

• DRUG INEFFECTIVE — 28,717 reports
• PSORIASIS — 22,567 reports
• PAIN — 16,136 reports
• ARTHRALGIA — 14,488 reports
• FATIGUE — 10,192 reports
• PSORIATIC ARTHROPATHY — 9,805 reports
• PRURITUS — 9,168 reports
• RASH — 8,709 reports
• CONDITION AGGRAVATED — 8,206 reports
• DIARRHOEA — 7,681 reports

Other Drugs Associated with MALAISE

The following drugs have also been linked to malaise in FDA adverse event reports:

Does SECUKINUMAB cause MALAISE?

MALAISE has been reported as an adverse event in 9,100 FDA reports for SECUKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is MALAISE with SECUKINUMAB?

MALAISE accounts for approximately 1.9% of all adverse event reports for SECUKINUMAB, making it a notable side effect.

What should I do if I experience MALAISE while taking SECUKINUMAB?

If you experience malaise while taking SECUKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages